What ICH M11 Is
ICH M11 is a harmonized guideline, template, and technical specification for interventional clinical trial protocols, developed through the International Council for Harmonisation (ICH) process. Its formal name is the Clinical electronic Structured Harmonised Protocol, usually abbreviated CeSHarP. Where earlier ICH guidelines (such as ICH E6(R2)) describe the principles a protocol must satisfy, ICH M11 goes a step further: it specifies the actual structure, headings, common text, and machine-readable data format a protocol document should use, so that protocols prepared by different sponsors, in different countries, follow a consistent and comparable shape.
ICH M11 consists of three linked deliverables:
- The guideline — the rationale and recommendations for adopting a harmonized, structured protocol format, including how it fits into a sponsor’s existing protocol development process.
- The template — a standardized content structure for interventional clinical trial protocols: common headers, section ordering, and boilerplate/instructional text for every section, applicable across trial phases and therapeutic areas, with both required and optional elements.
- The technical specification — the data standard that allows a protocol authored against the template to be exchanged electronically with regulators in a structured, machine-readable format, rather than only as a static PDF or Word document.
That third piece is what distinguishes ICH M11 from a purely editorial style guide: it is designed to work with structured-data initiatives already underway in the industry, including CDISC’s Unified Study Definitions Model (USDM), so that protocol content can eventually populate downstream systems — trial registries, data management plans, statistical analysis plans — without being re-keyed by hand.
Why a Harmonized Protocol Template Exists
Before ICH M11, protocol structure was governed only indirectly, through general principles in guidelines like ICH E6 and ICH E8(R1), and directly through whatever template a given sponsor, CRO, or academic institution had built internally. In practice, many large sponsors had already converged on something close to a shared structure via TransCelerate’s Common Protocol Template (see below), but there was no single structure recognized across FDA, EMA, and Japan’s PMDA — the three founding regulatory members of ICH — or the other regulatory authorities that have since joined ICH as members and observers. Reviewers at different agencies received protocols organized in different ways, which slowed review and made cross-jurisdictional comparison harder. ICH M11 addresses this directly, at the level of the harmonized guideline text itself rather than as informal industry convergence.
Adoption Status: FDA, EMA, and PMDA
ICH guidelines move through a five-step process: the ICH Assembly’s adoption of harmonized guideline text (Step 4) is followed by implementation into each ICH regulatory member’s own regulatory framework (Step 5), on that authority’s own timeline. For ICH M11:
- ICH Assembly: the M11 guideline, template, and technical specification were finalized and endorsed by the ICH Assembly, following an initial Step 2b public consultation on the guideline and template (October 2022–February 2023) and a second, separate consultation specifically on the technical specification (June 2025–July 2025).
- EMA/CHMP (EU): the European Medicines Agency’s Committee for Human Medicinal Products adopted ICH M11 as a Step 5 scientific guideline (reference EMA/CHMP/ICH/778799/2022), first published in December 2025.
- FDA (US): the FDA published its final ICH M11 guidance for industry — covering the guideline, template, and technical specification — in the Federal Register on May 22, 2026, following an earlier draft version issued for comment in 2022 and a second draft technical specification issued in mid-2025.
- PMDA (Japan) and other ICH regulatory members: as with every ICH guideline, implementation in Japan and in other ICH regulatory jurisdictions (including Health Canada and Swissmedic) proceeds on each authority’s own Step 5 timeline. Sponsors preparing submissions in those jurisdictions should confirm current implementation status directly with the relevant authority or via ich.org, since regional adoption dates are not simultaneous.
Because ICH M11 reached full Step 4 endorsement before regional Step 5 implementation was complete everywhere, sponsors should expect a transition period in which some authorities formally require or expect the M11 structure and others still accept protocols built on legacy templates. Checking the specific regulatory authority’s current guidance before submission — rather than assuming uniform global adoption — remains necessary.
How ICH M11 Relates to TransCelerate’s Common Protocol Template
TransCelerate Biopharma’s Common Protocol Template (CPT), first released roughly a decade before ICH M11’s finalization, was an industry-driven effort by TransCelerate’s member companies to converge on a shared, high-level protocol structure across sponsors — reducing the burden on investigators and sites who otherwise had to learn a different protocol layout for every study they participated in. Over successive versions, CPT adoption became widespread among large sponsors and many CROs.
ICH M11 does not scrap or compete with that groundwork — it formalizes and extends it into a regulator-endorsed, tripartite-harmonized standard, and TransCelerate was a substantive contributor to ICH M11’s development rather than a bystander to it. Following ICH M11’s finalization, TransCelerate member company subject-matter experts aligned the CPT (Basic Word edition) with the finalized ICH M11 template, technical specification, and CDISC’s Unified Study Definitions Model, so that a sponsor already using CPT is not starting from zero. In practice, the two are best understood as complementary rather than as one superseding the other:
- ICH M11 is the minimum, regulator-recognized harmonized structure and the electronic data-exchange format — the layer relevant to what a regulatory authority expects to receive.
- TransCelerate’s CPT retains additional granularity, instructional text, and sponsor-facing detail beyond what ICH M11 mandates, which many organizations have found useful for internal authoring consistency even where it goes beyond the regulatory minimum.
Sponsors and CROs already running on CPT are generally positioned to migrate toward ICH M11 alignment rather than to rebuild protocol authoring from scratch, though the technical-specification (structured data exchange) piece of ICH M11 is new territory for organizations that have only ever produced narrative protocol documents.
What This Means for Protocol Authors, Sponsors, and CROs
- Regulatory affairs and protocol authors should confirm which of their submission jurisdictions have moved to Step 5 implementation of ICH M11 and adjust protocol templates accordingly, rather than assuming a single global cutover date.
- Organizations already using TransCelerate’s CPT should review the CPT version aligned to ICH M11 rather than treating this as an unrelated, parallel migration.
- Clinical data management and biometrics teams have a direct stake in the technical specification component, since it is designed to interoperate with structured protocol data standards such as CDISC’s USDM — see our guide to clinical data management tools for how EDC, CDMS, and related systems fit into that data flow.
- Quality and compliance staff should treat the protocol template as one more artifact that needs to demonstrate consistency with ICH E6(R2) (and its R3 revision) principles and with sponsor obligations under ICH E6(R2) Section 5 — a structurally harmonized protocol does not change what GCP requires of its content, only how that content is organized and exchanged.
Frequently Asked Questions
What does ICH M11 stand for?
ICH M11 is the ICH guideline number; the guideline itself is formally named the Clinical electronic Structured Harmonised Protocol, abbreviated CeSHarP.
Is ICH M11 mandatory?
Whether ICH M11 is mandatory depends on the regulatory authority and jurisdiction, and on that authority’s own Step 5 implementation timeline. Sponsors should confirm current requirements directly with the specific regulator(s) they are submitting to rather than assume uniform global adoption.
Does ICH M11 replace TransCelerate’s Common Protocol Template?
No. TransCelerate was a substantial contributor to ICH M11’s development, and TransCelerate has since aligned its Common Protocol Template with the finalized ICH M11 template and technical specification. Many organizations use CPT’s additional detail alongside ICH M11’s regulator-recognized structure rather than choosing one over the other.
How is ICH M11 different from ICH M4 (the Common Technical Document)?
Both are ICH-harmonized structural standards, but they cover different documents. ICH M4 (the CTD) standardizes how a sponsor organizes and presents quality, nonclinical, and clinical information across an entire regulatory submission package. ICH M11 standardizes the structure of a single document within that broader process: the clinical trial protocol itself.
Does ICH M11 change what has to be in a protocol, or just its format?
ICH M11 primarily standardizes structure, headers, common text, and the electronic exchange format. The scientific and ethical content requirements a protocol must satisfy continue to come from guidelines such as ICH E6 and ICH E8(R1) on general trial design considerations.
Where can sponsors find the official ICH M11 documents?
The authoritative source for the guideline, template, and technical specification is ich.org, along with each regional regulator’s own implementation page (for example, the EMA’s scientific guideline page and the FDA’s guidance document database) — these should be checked directly for the current, region-specific status rather than relied on secondhand, since regional adoption timelines differ.
